

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

In re Patent Application of:  
Petra Lutter et al.

Application No.: 10/564,588

Confirmation No.: 3511

Filed: February 10, 2006

Art Unit: 1647

For: REGULATORY T-CELLS CONTAINING  
GALECTINS FOR THE THERAPY AND  
DIAGNOSIS OF DISEASES

---

Examiner: Davis S. Romeo

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The restriction requirement set forth in the Office action dated May 26, 2009 respectfully is traversed. Applicants respectfully contend that unity of invention is established among all claims 1-26. The Examiner restricted the claims into the following groups:

Group I – claims 1-11, and 20-26 (in part), drawn to a CD4+CD25+ T-cell comprising galectin-10, and

Group II – Claims 12-19 and 20-26 (in part), drawn to a binding agent that binds a CD4+CD25+ T-cell comprising galectin-10.

The Examiner has asserted that the inventions in Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical feature under PCT Rule 13.2, specifically, a CD4+CD25+ T-cell comprising galectin-10 as to Group I and a binding agent that binds a CD4+CD25+ T-cell comprising galectin-10 as